[ad_1]
By Davit Kirakosyan
10x Genomics, Inc. (NASDAQ:) shares dropped more than 12% after-hours following the company’s preliminary Q2 results, with revenue expected to be approximately $114.5 million (down 1% year-over-year), missing the Street estimate of $127.7 million.
“Our second quarter results fell short of our expectations,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “We continue to have strong confidence in our longer-term opportunity, technology leadership and the underlying strength of our markets. We are more excited than ever to deliver on the full potential of single cell and spatial biology.”
Hey there, slot game enthusiasts! If you're on the hunt for a thrilling online experience,…
A tidy environment helps employees focus better and creates an inviting atmosphere for visitors and…
Hey, gaming enthusiasts! If you're on the hunt for an exciting online game-playing experience, look…
Hi there, fellow gaming enthusiast! If you have ever wondered about the ins and outs…
Slot video game titles are one of the most popular forms of gambling establishment entertainment.…
Are you on a quest to discover the perfect scent that talks to your soul…